Evidence map›Paper›PMID 22821963›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2012

CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells.

Masakatsu Suzuki, Ann L Jagger, Christine Konya, Yasuhiro Shimojima, Sergey Pryshchep, Jörg J Goronzy, Cornelia M Weyand

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. A donor PD-1Signal transduction and targeted therapy · 2025
    Article
  3. Review
  4. CD8Journal of clinical medicine · 2023
    Article
  5. Age as a risk factor in vasculitis.Seminars in immunopathology · 2022
    Review
  6. Regulatory T Cells in Autoimmune Vasculitis.Frontiers in immunology · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Future prospects for CD8Immunological reviews · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Clinical significance of CCR7Scientific reports · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masakatsu SuzukiDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ann L Jagger
Christine Konya
Yasuhiro Shimojima
Sergey Pryshchep
Jörg J Goronzy
Cornelia M Weyand
Stanford University · US

Funding

VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
Vascular specific ACE expression and atherosclerosisP01HL058000 · NHLBI · VANDERBILT UNIVERSITY · PI DIKALOV, SERGEY · 1998 to 2013
$20.7M
Vaccination and infection: indicators of immunological health and responsivenessU19AI090019 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2010 to 2015
$17.3M
Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1993 to 2022
$4.8M
CD8 T CELLS IN RHEUMATOID SYNOVITISR01AI044142 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1999 to 2010
$2.9M
OCULAR DISEASE IN GIANT CELL ARTERITISR01EY011916 · NEI · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1997 to 2011
$2.9M
CD8 T cells in Rheumatoid ArthritisR56AI044142 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2013 to 2013
$369k
NEI NIH HHS EY 11916NEI NIH HHS R01 EY011916NHLBI NIH HHS HL 58000NHLBI NIH HHS P01 HL058000NIAID NIH HHS AI 44142NIAID NIH HHS AI 57266NIAID NIH HHS AI 90019NIAID NIH HHS R01 AI044142NIAID NIH HHS R56 AI044142NIAID NIH HHS U19 AI057266NIAID NIH HHS U19 AI090019NIAMS NIH HHS AR 42527NIAMS NIH HHS R01 AR042527
6 · The paper itself

Abstract

CD8 T cells stimulated with a suboptimal dose of anti-CD3 Abs (100 pg/ml) in the presence of IL-15 retain a naive phenotype with expression of CD45RA, CD28, CD27, and CCR7 but acquire new functions and differentiate into immunosuppressive T cells. CD8+CCR7+ regulatory T cells (Tregs) express FOXP3 and prevent CD4 T cells from responding to TCR stimulation and entering the cell cycle. Naive CD4 T cells are more susceptible to inhibition than memory cells. The suppressive activity of CD8+CCR7+ Tregs is not mediated by IL-10, TGF-β, CTLA-4, CCL4, or adenosine and relies on interference with very early steps of the TCR signaling cascade. Specifically, CD8+CCR7+ Tregs prevent TCR-induced phosphorylation of ZAP70 and dampen the rise of intracellular calcium in CD4 T cells. The inducibility of CD8+CCR7+ Tregs is correlated with the age of the individual with PBLs of donors older than 60 y yielding low numbers of FOXP3(low) CD8 Tregs. Loss of CD8+CCR7+ Tregs in the elderly host may be of relevance in the aging immune system as immunosenescence is associated with a state of chronic smoldering inflammation.

Indexed as

Immune ToleranceAdolescentAdultAgedAged, 80 and overAgingCD8 AntigensCell DeathCell DifferentiationForkhead Transcription FactorsHumansLeukocyte Common AntigensMiddle AgedPrimary Cell CultureReceptors, CCR7T-Lymphocytes, RegulatoryCD8 AntigensForkhead Transcription FactorsFOXP3 protein, humanLeukocyte Common AntigensReceptors, CCR7

Identifiers

PMID22821963
PMCPMC3424334
OpenAlexW2104829989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.